Other meanings of Postural orthostatic tachycardia syndrome
Health & Medicine
Postural orthostatic tachycardia syndrome (POTS) is a form of dysautonomia characterized by an excessive increase in heart rate upon standing, accompanied by symptoms such as dizziness, fatigue, and palpitations, in the absence of orthostatic hypotension. It is estimated to affect between 1 and 3 million people in the United States, predominantly women of childbearing age. The condition is often chronic and can significantly impair quality of life, though many patients improve with management strategies.
Postural orthostatic tachycardia syndrome is defined by a sustained heart rate increase of at least 30 beats per minute (or ≥40 bpm in adolescents) within 10 minutes of standing, without orthostatic hypotension (a drop of >20/10 mmHg). Symptoms include lightheadedness, palpitations, tremulousness, and exercise intolerance, which resolve on lying down. Diagnosis is typically made via tilt table testing or active stand test, after excluding other causes such as dehydration, medication side effects, or cardiac arrhythmias. The condition is classified as a form of dysautonomia, a disorder of the autonomic nervous system.
The exact mechanisms underlying POTS are heterogeneous and not fully understood. Three main subtypes are recognized: neuropathic (peripheral denervation of lower limbs), hyperadrenergic (excess sympathetic drive), and hypovolemic (reduced blood volume). Neuropathic POTS involves impaired vasoconstriction in the lower extremities, leading to blood pooling and compensatory tachycardia. Hyperadrenergic POTS is characterized by elevated norepinephrine levels upon standing, often with hypertension and palpitations. Hypovolemic POTS is associated with low blood volume, possibly due to renal sodium wasting or reduced red cell mass. Autoimmune involvement has been suggested, with some patients having antibodies against autonomic receptors, but this remains an area of active research.
Treatment of POTS is individualized and often multimodal. First-line measures include increased fluid and salt intake, compression garments, and physical countermaneuvers. Exercise training, particularly recumbent aerobic and resistance exercises, has been shown to improve symptoms and cardiovascular function. Pharmacologic options include beta-blockers (e.g., propranolol) to reduce heart rate, fludrocortisone to expand blood volume, and midodrine to increase peripheral vasoconstriction. For hyperadrenergic patients, central sympatholytics like clonidine may be used. Psychological support and cognitive-behavioral therapy are often beneficial, as anxiety and depression are common comorbidities. Most patients improve over time, but a subset remains severely disabled.
POTS has been linked to a range of lesser-known triggers and associations. It can be precipitated by viral infections, including Epstein-Barr virus and SARS-CoV-2, with a notable increase in cases following COVID-19. It is also associated with joint hypermobility syndromes, particularly Ehlers-Danlos syndrome, and with mast cell activation syndrome. A subset of patients experiences 'brain fog' severe enough to mimic attention deficit disorder. Historically, POTS was recognized in the 19th century as 'irritable heart' or 'soldier's heart' during the American Civil War, and later as 'neurocirculatory asthenia' in World War I. Despite its long history, it was only formally named in 1993 by Ronald Schondorf and Phillip Low. Research is ongoing into genetic factors, with some familial clustering reported.
This article is for informational purposes and does not replace professional medical advice.
Help improve the encyclopedia. Reports go straight to the site manager.